Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines—part 1: vitamins, minerals, and nutritional supplements

Noam Yarom \(^1,^2\) · Allan Hovan \(^3\) · Paolo Bossi \(^4\) · Anura Ariyawardana \(^5,^6\) · Siri Beier Jensen \(^7\) · Margherita Gobbo \(^8\) · Hanan Sac-Hazboun \(^9\) · Abhishek kandwal \(^10\) · Alessandra Majorana \(^11\) · Giulia Ottaviani \(^8\) · Monica Pentenero \(^12\) · Narmin Mohammed Nasr \(^13\) · Tanya Rouleau \(^14\) · Anna Skripnik Lucas \(^15\) · Nathaniel Simon Treister \(^16,^17\) · Eyal Zur \(^18\) · Vinisha Ranna \(^19\) · Anusha Vaddi \(^20\) · Karis Kin Fong Cheng \(^21\) · Andrei Barasch \(^22\) · Rajesh V. Lalla \(^23\) · Sharon Elad \(^20\) · On behalf of The Mucositis Study Group of the Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO)

Received: 26 January 2019 / Accepted: 22 May 2019
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Abstract

Purpose To update the clinical practice guidelines for the use of natural and miscellaneous agents for the prevention and/or treatment of oral mucositis (OM).

Methods A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. The findings were added to the database used to develop the 2014 MASCC/ISOO clinical practice guidelines. Based on the evidence level, the following guidelines were determined: Recommendation, Suggestion, and No Guideline Possible.

Results A total of 78 papers were identified within the scope of this section, out of which 29 were included in this part, and were analyzed with 27 previously reviewed studies. A new Suggestion was made for oral glutamine for the prevention of OM in head and neck (H&N) cancer patients receiving radiotherapy with concomitant chemotherapy. The previous Recommendation against the use of parenteral glutamine for the prevention of OM in hematopoietic stem cell transplantation (HSCT) patients was re-established. A previous Suggestion for zinc to prevent OM in H&N cancer patients treated with radiotherapy or chemoradiotherapy was reversed to No Guideline Possible. No guideline was possible for other interventions.

Conclusions Of the vitamins, minerals, and nutritional supplements studied for the management of OM, the evidence supports a Recommendation against parenteral glutamine in HSCT patients and a Suggestion in favor of oral glutamine in H&N cancer patients for the management of OM.

Keywords Oral mucositis · Natural · Herbal medicine · Glutamine · Zinc · Supersaturated calcium phosphate rinse · Guidelines

Introduction

Oral mucositis (OM) is a debilitating complication of cancer therapy, that in addition to pain, nutritional and psychosocial consequences can lead to treatment delays, breaks, and dose reductions, potentially influencing treatment outcomes \([1]\). Therefore, extensive research has been conducted to find a remedy for OM.

Natural remedies, including herbal extracts (botanicals) and dietary supplements, have been a topic for prolific research in OM. Nutritional supplements are perceived as a needed element in patients with an unbalanced diet. Likewise, many herbal agents are considered to promote wound healing or to have analgesic effects.
The Mucositis Study Group (MSG) of the Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO) has published clinical practice guidelines for OM [2–4]. In the 2014 guidelines update, the Natural and Miscellaneous section concluded the systematic review with 2 guidelines regarding vitamins, minerals, and nutritional supplements: (1) a Suggestion to use systemic zinc supplement to prevent OM in cancer patients receiving RT or RT-CT and (2) a Recommendation against the use of intravenous glutamine for the prevention of OM in patients receiving high-dose CT prior to hematopoietic stem cell transplantation (HSCT). No guideline was possible for any other agent [5, 6]. The aim of this project was to review newly acquired evidence and update the clinical practice guidelines for the use of natural and miscellaneous agents for the prevention and/or treatment of OM.

Methods

The methods are described in detail in Ranna et al. [7]. Briefly, a search for relevant papers indexed in the literature from January 1, 2011, to June 30, 2016, was conducted using Pubmed/Web of Science/EMBASE, with papers selected for review based on defined eligibility criteria.

Papers were reviewed by two independent reviewers and data were extracted using a standard electronic form. Studies were scored for their level of evidence (LoE) based on the Somerfield criteria, [8] and flaws were listed according to the Hadorn criteria [9]. A well-designed study was defined as a study with no major flaws per the Hadorn criteria.

Findings from the reviewed studies were merged with the evidence reviewed in the previous MASCC/ISOO guideline update. Then, findings from the reviewed studies were integrated into guidelines based on the overall LoE for each intervention. Guidelines were classified into 3 types: Recommendation, Suggestion, and No Guideline Possible.

Guidelines were specified based on the following variables: (1) the aim of the intervention (prevention or treatment of OM); (2) the treatment modality (RT, CT, RT-CT, or HSCT); and (3) the route of administration of the intervention.

The list of intervention keywords used for the literature search of the Natural and Miscellaneous section is presented in the Methods paper [7].

This report will cover the interventions categorized as vitamins, minerals, and nutritional supplements. The remaining agents will be described in the systematic review of Natural and Miscellaneous Agents for the Management of OM in Cancer Patients—Part 2.

Results

A total of 2653 papers were identified in the literature search: 1863 from PubMed and 790 from Web of Science. After careful assessment of the abstracts, 2563 articles were excluded due to repetition across databases, non-clinical studies, meta-analyses, and reviews. Three additional papers were transferred from other sections of the guidelines update. Ninety-three articles were retrieved for final review. After review of these full papers, 6 were moved to other sections, and 9 were excluded based on the eligibility criteria. A total of 78 papers are included in this section out of which 29 are included in this paper (part 1). These publications described 8 vitamins, minerals, and nutritional supplements and included in this part. These 29 new papers were merged with 27 publications that were reviewed in the previous guidelines update.

Zinc

Zinc is a vital electrolyte for homeostasis and is involved in biologic processes such as growth, wound healing, and immune reaction. Zinc is available in various forms, including zinc sulfate, zinc aspartate, and zinc L-carnosine. It is available commercially in combinations with other vitamins and elements. The specific compound affects the biologically available zinc dose. Table 1 summarizes the details of studies reviewed on zinc.

Zinc (systemic): H&N cancer, RT/RT-CT—prevention
Guideline: No guideline possible (LoE I)

The efficacy of systemic zinc administration for the prevention of OM in H&N cancer patients receiving RT or RT-CT was studied in 6 randomized controlled trials (RCT). Of these, 4 reported that zinc was effective for the prevention of OM [10, 13, 15, 18] and 2 reported that zinc was ineffective [16, 17]. In these studies, the RT dose ranged between 50 and 70 Gy and exceeded 60 Gy in most patients. However, reports were not comparable in terms of type of zinc preparations and doses. Zinc sulfate was used in 4 RCTs of which zinc was found to be effective in 2 RCTs [10, 18] and ineffective in the other 2 [16, 17]. The doses administered in these RCTs ranged between 90 and 150 mg/day elemental zinc [10, 16–18]. Zinc magnesium aspartate (75 mg per day) was found to be effective in the prevention of OM in a well-designed RCT and its subsequent sub-analysis [13, 14]. Zinc L-carnosine, a zinc-containing molecule, was found effective in preventing OM compared with 4% sodium gualenate hydrate mouthwash [15].

The efficacy of systemic zinc in preventing OM in H&N cancer patients was also evaluated in 2 case-control studies demonstrating conflicting results [11, 12].
Based on the evaluation of the quality of studies, the LoE is rated as I. Due to conflicting data about the efficacy, no guideline was possible.

**Zinc (systemic): HSCT—prevention**

**Guideline: No guideline possible (LoE II)**

There was a single RCT assessing systemic zinc for the prevention of OM in patients undergoing HSCT [19] and a case-control study [20]. Both studies showed no efficacy. The LoE was II and no guideline was possible.

**Zinc (systemic): Hematologic and solid cancers, CT—prevention**

**Guideline: No guideline possible (LoE III)**

There was a single RCT assessing systemic zinc administration for the prevention of OM in patients receiving CT for solid and hematologic malignancies [21]. This study concluded zinc was ineffective. The LoE was III and no guideline was possible.

**Zinc (topical): Hematologic patients, CT—prevention**

**Guideline: No guideline possible (LoE III)**

There was a single RCT assessing topical zinc administration for the prevention of OM in patients receiving CT for leukemia [22]. Zinc sulfate was compounded as a 0.2% mouthwash and the patients were instructed to rinse twice a day for 2 weeks. The topical zinc was compared with 0.2% chlorhexidine mouthwash. The zinc mouthwash was not superior to chlorhexidine mouthwash. The LoE was III and no guideline was possible.

**Supersaturated calcium phosphate rinse**

Supersaturated calcium phosphate rinses (SCPRs) contain high concentration of calcium and phosphate ions, allowing them to diffuse into the intercellular spaces of the epithelium [23]. The calcium and phosphate ions are hypothesized to play a significant role in inflammatory processes and tissue repair. Table 2 summarizes the details of studies reviewed on SCPR.
Supersaturated calcium phosphate rinse: HSCT—prevention
Guideline: No guideline possible (LoE III)

SCPR administered for the prevention of OM in patients undergoing HSCT was evaluated in 3 RCTs. Of these, 2 RCTs [24, 27] reported that SCPR was effective for the prevention of OM. A single RCT reported that it was ineffective [28]. This latter study compared a combination of SCPR and cryotherapy with cryotherapy alone. This study design may have reduced the risk of OM in both groups. Furthermore, in both study arms, 25% of the patients received reduced-intensity cytotoxic conditioning. These features in the study design might have hindered the SCPR’s effect (floor effect).

In addition, 1 comparative study and 1 cohort study have evaluated the efficacy of SCPR in preventing OM in patients undergoing HSCT [25, 26]. A comparison to historic control found that SCPR was effective [25] and the cohort study found it was effective only in a subgroup of patients receiving BEAM (carmustine, etoposide, cytarabine, and melphalan) as a conditioning regimen [26]. An additional study reported using SCPR as part of a multi-agent basic oral care protocol, which did not add information about the effect of SCPR alone [32]. Considering this literature, the LoE is III, and no guideline was possible.

Supersaturated calcium phosphate rinse: RT-CT—prevention
Guideline: No guideline possible (LoE III)

For SCPR administered for the treatment of OM in patients receiving RT (with or without CT) for H&N cancer, there was 1 RCT [30] showing no efficacy. There was also 1 comparative study showing ineffectiveness [31]. The LoE was III and no guideline was possible.

Glutamine

Glutamine is the most abundant amino acid in plasma and is a well-known nutrient used to increase cell proliferation as well as survival under metabolic stress conditions [33]. Glutamine is frequently used by rapidly dividing cells. In cancer patients, glutamine deficiency might develop, negatively affecting the function of host tissues [34]. Table 3 summarizes the details of studies reviewed on glutamine.

Glutamine (parenteral): HSCT—prevention
Guideline: Recommendation against (LoE I)

The efficacy of parenteral glutamine in the prevention of OM in patients undergoing HSCT was studied in 6 RCTs [35, 37–41]. Of these, there was a single study, conducted in pediatrics, published since the publication of the previous
### Table 3  
Studies reported for glutamine and elemental diet, overall level of evidence, and guideline determination

<table>
<thead>
<tr>
<th>Name of agent</th>
<th>Route of administration</th>
<th>Cancer</th>
<th>Treatment modality</th>
<th>Indication</th>
<th>Author, year</th>
<th>Effective</th>
<th>Overall level of evidence</th>
<th>Guideline category</th>
<th>Guideline determination</th>
<th>Guideline determination</th>
<th>Non-RCT studies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Schloerb 1999 [37]</td>
<td>N</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pytlik 2002 [38]</td>
<td>N</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Piccirillo 2003 [39]</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bljlevens 2005 [40]</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Uderzo 2011 [41] ^</td>
<td>N</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Coghlin 2000 [45]</td>
<td>N</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Aquino 2005 [46] ^</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PO</td>
<td>Parenteral</td>
<td>H&amp;N</td>
<td>RT-CT</td>
<td>P</td>
<td>Chattopadhyay 2014 [47]</td>
<td>Y</td>
<td>II</td>
<td>Suggestion</td>
<td>Oral glutamine at a dose of 10–30 g a day is suggested for the prevention of OM in H&amp;N cancer treated with radiotherapy or radio-chemotherapy. Caution (see text)</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Parenteral</td>
<td>Parenteral</td>
<td>Hematol</td>
<td>CT</td>
<td>P</td>
<td>Sornsuvit 2008 [50]</td>
<td>Y</td>
<td>III</td>
<td>NGP</td>
<td>–</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Anderson 1998b [55]</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Jebb 1994 [56]</td>
<td>N</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Choi 2007 [57]</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PO</td>
<td>Parenteral</td>
<td>Hematol</td>
<td>HSCT</td>
<td>P</td>
<td>–</td>
<td>N</td>
<td>IV</td>
<td>NGP</td>
<td>–</td>
<td></td>
<td>Morishita 2016 [58] – 4 (N)</td>
</tr>
<tr>
<td>PO</td>
<td>Parenteral</td>
<td>Solid ca.</td>
<td>CT</td>
<td>P</td>
<td>–</td>
<td>Y</td>
<td>III</td>
<td>NGP</td>
<td>–</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
guideline [41]. The glutamine regimens in all studies were comparable. Two RCTs [39, 40] found glutamine to be effective in preventing OM, while the 4 other RCTs [35, 37, 38, 41] did not demonstrate a beneficial effect. Moreover, in 1 RCT [38], a significant statistical correlation of glutamine treatment with relapse ($p = 0.02$) and mortality ($p = 0.05$) was documented [38]. Taking into account the lack of effectiveness in most studies as well as the potential risk, the panel decided to recommend against the use of parenteral glutamine for the prevention of OM in patients undergoing HSCT.

The LoE is I and the recommendation against is in line with the previous guideline about glutamine for this setting.

**Glutamine (PO): HSCT—prevention**

*Guideline: No guideline possible (LoE III)*

Three RCTs have evaluated the effectiveness of oral glutamine for the prevention of OM in patients undergoing HSCT [42, 45, 46]. In a single RCT [46], oral glutamine was found to be effective, in another RCT [45], it was ineffective, while the third RCT [42] found it to be effective only in patients who underwent autologous HSCT and ineffective in patients who underwent allogeneic HSCT. In addition, 2 non-RCTs have also reported conflicting results for the efficacy of oral glutamine in preventing OM in this patient population [43, 44]. In light of the above conflicting results, the LoE is III and no guideline was possible.

**Glutamine (PO): H&N cancer, RT-CT—prevention**

*Guideline: Suggestion (LoE II)*

Oral glutamine was found to be effective in preventing OM due to RT-CT in H&N cancer patients in 2 RCTs [47, 48]. In one RCT, 10 g of oral glutamine consumed 3 times a day throughout the concomitant RT-CT course, along the 6 weeks of treatment, significantly reduced the severity of OM and its associated pain [48]. In the other RCT, 10 g of oral glutamine given 2 h before RT, beginning at the first RT session and continued all along the RT course, significantly reduced the severity and duration of OM [47]. This study had a heterogeneous patient population, with 65% of the patients to receive RT with concurrent CT, and 35% of the patients receiving RT alone. Therefore, the LoE is II and the panel suggested the use of oral glutamine in H&N cancer patients undergoing RT-CT. The suggestion is with caution due to the higher mortality rate seen in HSCT patients treated with parenteral glutamine [38].

**Glutamine (topical): H&N cancer, RT—prevention**

*Guideline: No guideline possible (LoE III)*

A single RCT [49] demonstrated the effectiveness of topical glutamine in preventing OM in H&N cancer patients.
undergoing RT. LoE was classified as III. Therefore, it was not possible to provide any guideline.

Glutamine (parenteral): Hematologic malignancies, CT—prevention
Guideline: No guideline possible (LoE III)

A single RCT [50] has evaluated the benefit of parenteral glutamine in preventing OM in 16 AML patients undergoing chemotherapy (8 vs. 8 patients). This study, as well as 2 non-RCTs [34, 51], failed to demonstrate any beneficial effect of glutamine. Accordingly, LoE is III, and no guideline was possible.

Glutamine (PO): Solid cancers, CT—prevention
Guideline: No guideline possible (LoE II)

A RCT in breast cancer patients evaluating a rapid-uptake formulation of glutamine for the prevention of OM reported positive results [52]. Another small RCT in various solid tumors in pediatric and adult patients reported oral glutamine to be effective in the prevention of OM [55]. Two additional cohort studies involving small patient populations (n = 9 and n = 14) also suggested oral glutamine to be effective [53, 54]. Due to the variability in the glutamine formulation and the patient population, no guideline is possible.

Elemental diet

Elemental diet (ED) formulations have been widely used in Japan for improving nutritional status in patients [61]. These formulas contain amino acids, carbohydrates, vitamins, minerals, and minimal fat and are considered to be a good source of L-glutamine.

Elemental diet (PO): HSCT—prevention
Guideline: No guideline possible (LoE IV)

The use of an ED for the prevention of OM in patients undergoing HSCT was assessed in a single cohort study [58] and found to be ineffective. Therefore, no guideline was possible.

Elemental diet (PO): Solid cancers, CT—prevention
Guideline: No guideline possible (LoE III)

A small RCT [59] tested the efficacy of ED for the prevention of OM in a heterogeneous group of cancer patients treated with chemotherapy. Ten patients were treated with glutamine, 10 patients were treated with both glutamine and ED, and an additional 10 patients received neither glutamine nor ED and served as the control group. The incidence of grade ≥2 OM was the highest in the glutamine group, followed by the control group, and the least in the glutamine plus ED group (p = 0.04). ED was found to be effective also in a cohort study of 22 colorectal cancer patients treated with 5-fluorouracil (FU)-based chemotherapy [60].

Elemental diet (PO, swish and swallow): H&N cancer, RT/RT-CT—prevention
Guideline: No guideline possible (LoE IV)

A single retrospective cohort study evaluating the use of ED for the prevention of OM associated with RT (with or without CT) demonstrated that the degree of OM was much lower in patients using ED [61]. Since it was applied as swish and swallow, it is assumed to have both topical and systemic effect.

Vitamin E

Vitamin E refers to eight fat-soluble compounds (α-, β-, γ-, δ-tocopherol, and α-, β-, γ-, δ-tocotrienol) that act as antioxidants. α-Tocopherol, the most common form of vitamin E in human tissues, is considered to have cytoprotective and anti-inflammatory properties [62]. Table 4 summarizes the details of studies reviewed on vitamin E.

Vitamin E (PO, swish and swallow): Hematologic patients, CT—treatment
Guideline: No guideline possible (LoE III)

A single RCT [63] compared the efficacy of swish and swallow vitamin E, pycnogenol, and glycerin (vehicle-control) for the treatment of OM in 72 pediatric patients receiving CT for hematologic malignancies. Both vitamin E and pycnogenol were found to be effective compared with the vehicle (p < 0.001 each). However, there was no significant difference between the efficacy observed in the active arms (p = 0.89).

Another RCT compared vitamin E tablets to vitamin E oil swish and swallow [67]. There was no control arm in this study. The study recruited 80 children who were undergoing CT for hematological malignancies, 40 in each arm. Vitamin E swish and swallow was superior to vitamin E pills in the treatment of OM (p < 0.001).

Vitamin E (topical): Solid cancer, CT—treatment
Guideline: No guideline possible (LoE III)

A single RCT evaluated vitamin E for the treatment of OM in 17 solid cancer patients receiving CT [64]. Vitamin E mouthwash shortened the duration of OM (p = 0.025). No other studies in this category were identified. Therefore, no guideline is possible.
**Vitamin E (topical): Solid cancers, CT—prevention**

Guideline: No guideline possible (LoE III)

Topical vitamin E was tested for the prevention of OM in a RCT enrolling 16 pediatric patients treated with CT [65]. It is unclear how many patients were enrolled in each arm as the study reported the sample size in terms of cycles of treatment. Most of these patients were diagnosed with solid cancer. There was no difference between the groups in regard to OM severity.

**Vitamin E (swish and swallow): H&N cancer, RT—prevention**

Guideline: No guideline possible (LoE II)

The efficacy of vitamin E for the prevention of OM in H&N cancer patients treated with RT was tested in a RCT [66]. Vitamin E was applied as a swish and swallow oil. This RCT concluded that vitamin E is effective (p = 0.038). No other studies were available in this category. Therefore, no guideline is possible.

---

**Selenium**

Selenium is an essential trace element with anti-oxidative and anti-inflammatory properties. It is an important cofactor for glutathione peroxidase, which scavenges free radicals [68]. Table 5 summarizes the details of studies reviewed on selenium.

**Selenium (PO): HSCT—prevention**

Guideline: No guideline possible (LoE III)

The efficacy of oral selenium for the prevention of OM in patients treated with high-dose CT as a part of the conditioning regimen prior to HSCT was evaluated in a single RCT [69]. Selenium was found to be effective in reducing the severity and duration of OM. No other studies on the efficacy of selenium in preventing OM were identified; therefore, no guideline was possible.

---

**Table 4**  
Studies reported for vitamin E, overall level of evidence, and guideline determination

<table>
<thead>
<tr>
<th>Name of agent</th>
<th>Route of administration</th>
<th>Cancer Treatment modality</th>
<th>Indication</th>
<th>Author, year</th>
<th>Effective</th>
<th>Overall level of evidence</th>
<th>Guideline category</th>
<th>Guideline determination</th>
<th>Non-RCT studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vit. E</td>
<td>SS</td>
<td>Hematol ^ CT T</td>
<td>T</td>
<td>Khurana 2013 [63]</td>
<td>Y</td>
<td>III</td>
<td>NGP</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Vit. E</td>
<td>Topical</td>
<td>Solid CT T</td>
<td>P</td>
<td>Sung 2007 [65]</td>
<td>N</td>
<td>III</td>
<td>NGP</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Vit. E</td>
<td>SS</td>
<td>H&amp;N RT P</td>
<td>Ferreira 2004 [66]</td>
<td>Y</td>
<td>II</td>
<td>NGP</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Non-RCT studies key: 3. non-RCT, 4. cohort, 5. before and after, 6. case-control studies, 7. cross-sectional, 8. case series, 9. case report, 10. expert opinion

NGP, no guideline possible; Vit., vitamin; RCT, randomized controlled trial; hematol, hematological; CT, chemotherapy; H&N, head and neck; ca., cancer; P, prevention; N, no, ineffective; Y, yes, effective; PO, per os; NGP, no guideline possible; S&S, swish and swallow

^Pediatric patient population

---

**Table 5**  
Studies reported for other vitamins and minerals, overall level of evidence, and guideline determination

<table>
<thead>
<tr>
<th>Name of agent</th>
<th>Route of administration</th>
<th>Cancer Treatment modality</th>
<th>Indication</th>
<th>Author, year</th>
<th>Effective</th>
<th>Overall level of evidence</th>
<th>Guideline category</th>
<th>Guideline determination</th>
<th>Non-RCT studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>selenium</td>
<td>PO</td>
<td>Hematol HSCT P</td>
<td>Jahangard 2013 [69]</td>
<td>Y</td>
<td>III</td>
<td>NGP</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Folinic</td>
<td>PO/topical</td>
<td>Hematol HSCT P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NGP</td>
<td>Sugita 2012 [70] – 4 (Y)</td>
<td></td>
</tr>
<tr>
<td>Calcitriol</td>
<td>PO</td>
<td>Hematol HSCT P</td>
<td>Hamidieh 2015 [71]</td>
<td>N</td>
<td>II</td>
<td>NGP</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Non-RCT studies key: 3. non-RCT, 4. cohort, 5. before and after, 6. case-control studies, 7. cross-sectional, 8. case series, 9. case report, 10. Expert opinion

NGP, no guideline possible; RCT, randomized controlled trial; hematol, hematological; HSCT, hematopoietic stem cell transplantation; ca., cancer; P, prevention; N, no, ineffective; Y, yes, effective; PO, per os; NGP, no guideline possible

^Pediatric patient population
Folinic acid

Methotrexate (MTX) is one of the most widely used anticancer agents. Folinic acid, also known as leucovorin, is considered to reverse the action of MTX and therefore is usually used in cases of MTX toxicity [72]. Table 5 summarizes the details of studies reviewed on folinic acid.

Folinic acid (PO/topical): HSCT—prevention
Guideline: No guideline possible (LoE IV)

Our literature search failed to identify any RCT assessing the efficacy of folinic acid for the prevention of OM in patients undergoing HSCT. A single cohort study [70] found systemic folinic acid to be effective in preventing MTX-induced OM in patients undergoing HSCT ($p = 0.014$). A trend toward efficacy in preventing OM was found for folinic acid mouthwash ($p = 0.051$). Considering the LoE, no guideline was possible.

Calcitriol

Calcitriol, also called 1,25-dihydroxycholecalciferol, is the active metabolite of vitamin D. Vitamin D is a group of fat-soluble hormones responsible for increasing intestinal absorption of calcium, magnesium, and phosphate [73]. Vitamin D is speculated to have anti-inflammatory properties related to its ability to diminish the release of TNF-α and to increase the synthesis of interleukin10 [71]. Table 5 summarizes the details of studies reviewed on calcitriol.

GCalcitriol (PO): HSCT—prevention
Guideline: No guideline possible (LoE III)

The use of calcitriol for prevention of OM in patients undergoing HSCT was evaluated in a single RCT [71]. Twenty-eight patients with Fanconi anemia undergoing HSCT were treated with either oral calcitriol or placebo. There was no difference in OM incidence or severity between the two groups.

Discussion

This systematic review is the first part of the update about natural and miscellaneous agents for the management of OM. This part included literature about minerals, vitamins, and supplemental diet. Based on the literature review, several changes have been made to the MASCC/ISOO clinical practice guidelines for the management of OM.

In regard to glutamine, parenteral administration in HSCT patients in order to prevent OM yielded a Recommendation against its use. This guideline appeared in the previous guidelines [6]; however, the LoE was elevated from II to I due to a new well-designed RCT [41]. A new Suggestion was made for oral glutamine in H&N cancer patients treated with RT-CT for the prevention of OM. This guideline is based on 2 new RCTs [47, 48]. These studies demonstrated that glutamine at a dose range of 10–30 mg/day, delivered throughout the RT-CT, may be effective to prevent OM. This positive guideline for PO glutamine takes into account the negative guideline for parenteral glutamine by attaching a note to this guideline and advising caution due to the higher relapse and mortality rate in parenteral glutamine administration in HSCT patients [38]. It is unclear if the discrepancy between the outcome of parenteral glutamine in HSCT and PO glutamine for RT-CT relies on the mode of administration or on the different underlying diseases and treatment modalities. Of note, in one of the RCTs used to develop this Suggestion, oral glutamine was delivered as a swish-and-swallow [47], and there may be a combined topical and systemic effect in this study.

In regard to zinc, this guideline update reverses the Suggestion made for zinc in the 2014 MASCC/ISOO guidelines for H&N cancer patients treated with RT or RT-CT [4]. This guideline change is based on 2 new RCTs that reported a lack of effectiveness [16, 17]. It is noted that there is an additional new RCT that confirmed the previous RCTs showing positive results with zinc [18]. However, due to the conflicting evidence, it is impossible to conclude a positive effect for zinc.

The publications about zinc used various compounds. The guideline generalized the conclusion because the number of studies was too low to break down the evidence by specific zinc compound. Based on the current evidence, it is impossible to tell if a certain type of zinc is superior compared with other types of zinc in respect of OM prevention. Since the absorption of the zinc is depended on the zinc compound (for example, out of 220-mg zinc sulfate, 50-mg elemental zinc is bioavailable), it is advised to specify in future research the type of zinc compound.

In regard to SCPR, 2 RCTs in patients undergoing HSCT showed some level of effectiveness, while another RCT found that SCPR did not confer any additional benefit in HSCT patients receiving cryotherapy. Evidence from other types of studies was also conflicting. Therefore, the panel concluded that there was conflicting evidence that warrants additional studies prior to instituting a guideline [24, 27, 28].

Other vitamins and minerals for which the literature search identified new studies include vitamin E, selenium, folic acid, and calcitriol. Due to limited evidence, no guideline was possible for any of these vitamins and minerals. Furthermore, when a combination protocol was studied, the nature of the mixed intervention did not allow a conclusion about any particular component of the combination [74]. While the previous guideline update identified several studies about vitamin A effects on OM [6], no new studies were found on this topic in this review.
Therefore, the status of the previous guideline is unchanged—no guideline possible.

While the timeframe of this literature review ended in mid-2016, several RCTs on the management of OM were published since then. Although not influencing the present guidelines, they are worth mentioning: In a single RCT, oral glutamine has significantly delayed the onset as well as the severity of OM in H&N cancer patients receiving RT-CT [75]. However, glutamine was found to be ineffective in another RCT [76], although it slightly reduced OM compared with placebo. Additionally, a large prospective cohort study has found oral glutamine to be effective in preventing OM [77]. Likewise, a non-blinded RCT in solid cancer patients treated with CT reported that glutamine formulated as sodium azulene sulfonate L-glutamine was effective in preventing OM [78].

Publications post-mid-2016 were also found for ED. A small RCT has evaluated the efficacy of ED in preventing CT-induced OM in esophageal cancer patients [79]. The severity of OM was significantly lower in the ED arm as reported by the patients, but not as measured by the providers. Another RCT failed to demonstrate a beneficial effect of ED in preventing OM in esophageal cancer patient treated with RT with or without concomitant CT [80].

In the search for recently published articles about zinc, a RCT reported that zinc sulfate reduced the incidence and severity of OM in leukemia patients undergoing CT [81]. Additionally, zinc was reported to be effective in 2 comparative studies; one conducted in HSCT and the second conducted in RT for H&N cancer [12, 82].

A search for recently published articles about SCPR identified a large RCT, which concluded that SCPR was ineffective in the management of OM in H&N cancer patients treated with RT/RT-CT [83]. A recent RCT in pediatric patients [84] and comparative studies about SCPR indicated conflicting results about the effectiveness in preventing OM [23, 85].

In summary, for the interventions reviewed in this paper, the available evidence supported guidelines for glutamine. Likewise, based on additional evidence, we reversed a previous guideline for zinc. Considering the growing body of evidence, the guidelines about the agents covered in this section will require updating in the future.

Acknowledgments The authors are thankful for the medical librarians for their valuable contribution to this project:

Lorraine Porcello, MSLIS, MSIM – Bibby Dental Library, Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, NY, USA; Daniel A. Castillo, MLIS – Edward G. Miner Library, University of Rochester Medical Center, Rochester, NY, USA.

Compliance with ethical standards

Conflict of interest Per the MASCC Guidelines Policy, employees of commercial entities were not eligible to serve on this MASCC Guidelines Panel.

The authors disclose no conflict of interest (NY, AH, AA, SJ, MG, HIH, AK, AM, GO, MP, NMN, TR, ASL, NST, EZ, VR, AV, KF, AB, SE). PB has served an advisory role for AstraZeneca, Helsinn, and Kyowa Kyorin and received grants from Merck, Kyowa Kyorin, and Roche. RVL has served as a consultant for Colgate Oral Pharmaceuticals, Galera Therapeutics, Ingalfaarma SA, Monopar Therapeutics, Mundipharma, and Sucampo Pharma; has received research support to his institution from Galera Therapeutics, Novartis, Oragenics, and Sucampo Pharma; and has received stock in Logic Biosciences.

References

Polaprezinc reduces the severity of radiation-induced mucositis in head and neck cancer patients. Mol Clin Oncol 3:381–386


patients receiving MTX as prophylaxis for GVHD. Bone Marrow Transplant 47:258–264

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Affiliations

Noam Yarom1,2 · Allan Hovan3 · Paolo Bossi4 · Anura Ariyawardana5,6 · Siri Beier Jensen7 · Margherita Gobbo8 · Hanan Saca-Hazboun9 · Abhishek kandwal10 · Alessandra Majorana11 · Giulia Ottaviani8 · Monica Pentenero12 · Anura Mohammed Nasr13 · Tanya Rouleau14 · Anna Skripnik Lucas15 · Nathaniel Simon Treister16,17 · Eyal Zur18 · Vinisha Ranna19 · Anusha Vaddi20 · Karis Kin Fong Cheng21 · Andrei Barasch22 · Rajesh V. Lalla23 · Sharon Elad20

1 Oral Medicine Unit, Sheba Medical Center, Tel Hashomer, Israel
2 School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel
3 British Columbia Cancer - Vancouver Centre, Vancouver, Canada
4 Medical Oncology, ASST-Spedali Civili, University of Brescia, Brescia, Italy
5 College of Medicine and Dentistry, James Cook University, Cairns, Queensland, Australia
6 Metro South Oral Health, Queensland Health, Brisbane, Australia
7 Department of Dentistry and Oral Health, Faculty of Health, Aarhus University, Aarhus, Denmark
8 Division of Oral Medicine and Pathology, Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy
9 Al-Maha Cancer foundation, Bethlehem, Palestine
10 Cancer Research Institute, Himalayan Institute of Medical Sciences, Swami Ram Institute of Medical Science, Dehradun, Uttarakhand, India
11 Department of Medical and Surgical Specialties, Radiological Science and Public Health, Dental School University of Brescia, Brescia, Italy
12 Department of Oncology, Oral Medicine and Oral Oncology Unit, University of Turin, Turin, Italy
13 Special Needs Dentistry, Dental Services, Directorate General of Health Services-Muscat Governorate, Ministry of Health, Muscat, Oman
14 Dental Oncology Program, Health Sciences North, North East Cancer Center, Sudbury, ON, Canada
15 Medical Oncology Service, Department of Medicine, NYU Langone Perlmutter Cancer Center, New York, NY, USA
16 Division of Oral Medicine and Dentistry, Brigham and Women’s Hospital, Boston, MA, USA
17 Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, USA
18 Compounding Solutions, Tel-Mond, Israel
19 Department of Oral and Maxillofacial Surgery, The Mount Sinai Hospital, New York, NY 10029, USA
20 Oral Medicine, Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, NY, USA
21 Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
22 Division of Oncology, Weill Cornell Medical College, New York, NY, USA
23 Section of Oral Medicine, University of Connecticut School of Dental Medicine, Farmington, CT, USA